Karl D. Handelsman

Karl D.
Handelsman is the founder of Codon Innovation LLC, which was founded in 2013.
He is currently working as an Investment Director at Roche Ventures since 2017.
Additionally, he holds director positions at Good Therapeutics, Inc. and Bonum Therapeutics, Inc. Mr. Handelsman has previously worked as a Director of Business Development at Millennium Pharmaceuticals, Inc. from 1996 to 1997.
He also served as an Independent Director at Tetraphase Pharmaceuticals, Inc. in 2013.
From 1999 to 2013, he was a Managing Director at Presidio Partners.
Mr. Handelsman has held director positions at Neos Therapeutics, Inc., Intellikine LLC, Velocity Pharmaceutical Development LLC, Tularik, Inc., and Whitehead Institute for Biomedical Research.
He completed his graduate degree at Harvard University, undergraduate degree at Boston University, and obtained an MBA from Massachusetts Institute of Technology.